Can Regeneron (REGN)'s Rare-Disease Win Move the Earnings Needle?
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 1,126,080 | $702,155,889 | -9% | 0.24% |
| 2. | GLG Partners Noam Gottesman | 436,956 | $272,459,544 | +39% | 0.43% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 393,685 | $245,478,345 | +130% | 0.11% |
| 4. | 271,300 | $169,166,402 | +27% | 0.02% | |
| 5. | 264,600 | $164,988,684 | +54% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $800.00 | 400 | $320,000.00 | 603 | 2026-08-10 | Filing | |
| $800.00 | 800 | $640,000.00 | 1,703 | 2026-08-10 | Filing | |
| $650.15 | 200 | $130,030.00 | 17,303 | 2026-07-02 | Filing | |
| $714.13 | 2 | $1,428.26 | 17,503 | 2026-05-01 | Filing | |
| $712.09 | 1 | $712.09 | 17,505 | 2026-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,113,506 | $5,682,635,642 | 0.08% | |
| 2. | 6,629,759 | $4,133,919,926 | 0.09% | |
| 3. | 4,871,137 | $3,037,348,765 | 1.59% | |
| 4. | 4,834,688 | $3,014,621,356 | 0.09% | |
| 5. | 3,940,665 | $2,457,161,872 | 0.19% |
News See All
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here.
Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims
A class action lawsuit was filed against biotechnology company Regeneron ($REGN) on July 16, which could put further pressure on its troubled share...
The Week That Was, The Week Ahead: Macro and Markets, August 16
U.S. stocks ended another positive week near record highs, although Friday’s weak retail sales report took some of the shine off the rally. The S&P...
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology.
Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2
Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here.
Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks on our list.
10 Best Innovative Healthcare Stocks to Buy Now
In this article, we will be taking a look at the 10 Best Innovative Healthcare Stocks to Buy Now. The U.S.
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) - Here's Why
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best non-tech stocks to buy according to analysts. RBC Capital maintained a Sector Perform rating on Regeneron Pharmaceuticals, Inc.
Hedge Fund Resource Center